Genocea Biosciences Inc (OTCPK:GNCAQ)

$ 0.0001 0 (0%) Market Cap: - Enterprise Value: -4.65 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Genocea Biosciences Inc at Needham Healthcare Conference Transcript
Apr 12, 2022
Genocea Biosciences Inc at American Association for Cancer Research (AACR) Investor Webinar Transcript
Apr 08, 2022
Q4 2021 Genocea Biosciences Inc Earnings Call Transcript
Mar 10, 2022

$1.17 (-1.68%)

Earnings
Q3 2021 Genocea Biosciences Inc Earnings Call Transcript
Oct 28, 2021

$1.8 (+7.78%)

Earnings
Q2 2021 Genocea Biosciences Inc Earnings Call Transcript
Jul 29, 2021

$2.04 (+0.49%)

Earnings
Q1 2021 Genocea Biosciences Inc Earnings Call Transcript
Apr 29, 2021

$2.66 (+2.31%)

Earnings
Q4 2020 Genocea Biosciences Inc Earnings Call Transcript
Feb 11, 2021

$3.28 (-2.96%)

Earnings
Genocea Biosciences, Inc. - Special Call Transcript
Nov 09, 2020
Q3 2020 Genocea Biosciences Inc Earnings Call Transcript
Oct 29, 2020

$2.12 (-6.61%)

Earnings
Q2 2020 Genocea Biosciences Inc Earnings Call Transcript
Jul 23, 2020

$3.6 (+14.65%)

Earnings
Genocea Biosciences Inc Annual Shareholders Meeting Transcript
Jun 01, 2020
Genocea Biosciences, Inc. - Shareholder/Analyst Call Transcript
May 12, 2020
Q1 2020 Genocea Biosciences Inc Earnings Call Transcript
Apr 30, 2020

$2.28 (+1.33%)

Earnings
Q4 2019 Genocea Biosciences Inc Earnings Call Transcript
Feb 13, 2020

$2.18 (-3.33%)

Earnings
Q3 2019 Genocea Biosciences Inc Earnings Call Transcript
Oct 24, 2019

$2.45 (-6.49%)

Earnings
Q2 2019 Genocea Biosciences Inc Earnings Call Transcript
Jul 25, 2019

$3.53 (-7.11%)

Earnings
Genocea Biosciences, Inc. - Special Call Transcript
Jun 03, 2019
Q1 2019 Genocea Biosciences Inc Earnings Call Transcript
Apr 30, 2019

$5.6 (-7.89%)

Earnings
Q4 2018 Genocea Biosciences Inc Earnings Call Transcript
Feb 28, 2019

$5.84 (-18.89%)

Earnings

Genocea Biosciences Inc at Needham Healthcare Conference Transcript

Apr 12, 2022 / 06:15PM GMT

Release Date Price: $0.49 (-18.33%)

Transcript

Gil Blum

Needham & Company, LLC - Analyst

Good afternoon, and welcome to day 2 of the Annual Needham & Company Healthcare Conference. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company, covering the immuno-oncology and gene therapy subsectors.

It is my pleasure to have with me today Chip Clark, the CEO of Genocea. (Conference Instructions) And with that, Chip, you have the stage.

Chip Clark

Genocea Biosciences, Inc. - President & CEO

Thanks, Gil, and thank you to Needham for the opportunity to represent my colleagues back here in Cambridge, Massachusetts at Genocea where we will talk today about our work to develop next-generation neoantigen-targeted cancer immunotherapies. I will be making forward-looking statements today and so please be mindful of that fact.

Here is our story in a nutshell. We believe that our products are differentiated because they are designed that way. We have built the company around what we believe to be a differentiated neoantigen discovery platform that we call ATLAS.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.